171 related articles for article (PubMed ID: 36843367)
21. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.
Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A
Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927
[TBL] [Abstract][Full Text] [Related]
22. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis.
Thomas D; Radhakrishnan P
Mol Cancer; 2019 Jan; 18(1):14. PubMed ID: 30665410
[TBL] [Abstract][Full Text] [Related]
23. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
Li Y; Zhao Z; Lin CY; Liu Y; Staveley-OCarroll KF; Li G; Cheng K
Theranostics; 2021; 11(5):2182-2200. PubMed ID: 33500719
[No Abstract] [Full Text] [Related]
24. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
25. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
26. Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk.
Qin H; Chen J; Bouchekioua-Bouzaghou K; Meng YM; Griera JB; Jiang X; Kong X; Wang M; Xu Q; Wong PP
J Transl Med; 2023 Oct; 21(1):702. PubMed ID: 37814317
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic cancer stroma: an update on therapeutic targeting strategies.
Hosein AN; Brekken RA; Maitra A
Nat Rev Gastroenterol Hepatol; 2020 Aug; 17(8):487-505. PubMed ID: 32393771
[TBL] [Abstract][Full Text] [Related]
28. Generation of an in vitro 3D PDAC stroma rich spheroid model.
Ware MJ; Keshishian V; Law JJ; Ho JC; Favela CA; Rees P; Smith B; Mohammad S; Hwang RF; Rajapakshe K; Coarfa C; Huang S; Edwards DP; Corr SJ; Godin B; Curley SA
Biomaterials; 2016 Nov; 108():129-42. PubMed ID: 27627810
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic cancer stroma: controversies and current insights.
Ansari D; Carvajo M; Bauden M; Andersson R
Scand J Gastroenterol; 2017; 52(6-7):641-646. PubMed ID: 28276831
[TBL] [Abstract][Full Text] [Related]
30. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.
Stouten I; van Montfoort N; Hawinkels LJAC
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052
[TBL] [Abstract][Full Text] [Related]
31. The nanobody targeting PD-L1 and CXCR4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment.
Li Y; Zheng Y; Xu S; Hu H; Peng L; Zhu J; Wu M
Int Immunopharmacol; 2024 May; 132():111944. PubMed ID: 38581990
[TBL] [Abstract][Full Text] [Related]
32. A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma.
Drifka CR; Eliceiri KW; Weber SM; Kao WJ
Lab Chip; 2013 Oct; 13(19):3965-75. PubMed ID: 23959166
[TBL] [Abstract][Full Text] [Related]
33. Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment.
Luo Y; Li C; Zhang Y; Liu P; Chen H; Zhao Z; Wang Y; Zhou Z; Song H; Su B; Li C; Li X; Zhang T; You H; Wu Y; Tian Z; Zhang S; Guo Y; Fan H; Chen Q; Jiang C; Sun T
Acta Biomater; 2023 Sep; 167():387-400. PubMed ID: 37276955
[TBL] [Abstract][Full Text] [Related]
34. [Epithelial-stromal interactions in pancreatic adenocarcinoma: the role of stroma in disease progression].
Kuznetsova AV; Popova OP; Astakhov DA; Ivanov YV; Panchenkov DN; Ivanov AA
Arkh Patol; 2022; 84(5):65-70. PubMed ID: 36178225
[TBL] [Abstract][Full Text] [Related]
35. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
36. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer.
Ahmad RS; Eubank TD; Lukomski S; Boone BA
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34204306
[TBL] [Abstract][Full Text] [Related]
37. Targeting Pancreatic Stellate Cells in Cancer.
Schnittert J; Bansal R; Prakash J
Trends Cancer; 2019 Feb; 5(2):128-142. PubMed ID: 30755305
[TBL] [Abstract][Full Text] [Related]
38. Development of a novel co-culture system using human pancreatic cancer cells and human iPSC-derived stellate cells to mimic the characteristics of pancreatic ductal adenocarcinoma in vitro.
Kometani T; Kamo K; Kido T; Hiraoka N; Chibazakura T; Unno K; Sekine K
Biochem Biophys Res Commun; 2023 May; 658():1-9. PubMed ID: 37004297
[TBL] [Abstract][Full Text] [Related]
39. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
40. Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight.
Sato N; Kohi S; Hirata K; Goggins M
Cancer Sci; 2016 May; 107(5):569-75. PubMed ID: 26918382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]